TP

Tirunelveli Padmanabhan Devarajan

Active Director Nominee Director DIN 03473633
DIN 03473633 First appointment Mar 2011 Primary industry Internet
Unlock full profile Investments · shareholding · contact details
Current companies 8 active board seats
Past companies 5 historical roles
Total affiliations 13 Since Mar 2011
Shareholding value •••• Premium profile

About Tirunelveli Padmanabhan Devarajan

Data last updated:

Tirunelveli Padmanabhan Devarajan is a Nominee Director at Phasorz Technologies Private Limited (since 2021), Nominee Director at Phasorz Technologies Private Limited (since 2021) and Nominee Director at Malladi Drugs And Pharmaceuticals Limited (since 2022), and holds 5 more current directorships. The companies operate in Internet, Pharma and Healthcare. The 7 current companies with reported revenue have a combined latest revenue of ₹2,915 Cr; the largest is Phasorz Technologies Private Limited at ₹743 Cr (FY 2025). Earlier, Tirunelveli Padmanabhan Devarajan was a Director at Sreyas Holistic Remedies Private Limited (2014–2023) and Nominee Director at Stericon Pharma Private Limited (2017–2023) and 3 more.

DIN 03473633
Primary Designation Nominee Director
Industry Internet
First Appointment 14 Mar 2011
Oldest Company Age 46 yrs
Largest company Phasorz Technologies Private Limited · ₹743 Cr (FY 2025)
Combined revenue ₹2,915 Cr across 7 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Phasorz Technologies Private Limited U72300TN2013PTC092385
Nominee Director08 Jan 20212013₹743 Cr (FY 2025)Active
Phasorz Technologies Private Limited U86100TN2013PTC092385
Nominee Director08 Jan 20212013₹743 Cr (FY 2025)Active
Nominee Director28 Mar 20221980₹627 Cr (FY 2025)Active
Nominee Director17 Jul 20192011₹483 Cr (FY 2025)Active
Director27 Mar 20172005₹193 Cr (FY 2023)Active
Alniche Lifesciences Private Limited U51909DL2012PTC244770
Director31 May 20182012₹120 Cr (FY 2025)Active
Sandor Life Sciences Private Limited U85110TG2004PTC043672
Director08 Jan 20162004₹6.02 Cr (FY 2021)Active
Designated Partner17 Oct 20222022Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director15 Feb 20142008₹114 Cr (FY 2025)Active
Stericon Pharma Private Limited U33201KA1990PTC011056
Nominee Director02 Jan 20171990₹169 Cr (FY 2025)Active
Director07 Dec 20122012₹61.52 Cr (FY 2017)Amalgamated
Fermenta Biotech Limited U99999MH1986PLC134021
Alternate Director14 Mar 20111986₹401 Cr (FY 2019)Amalgamated
Alternate Director07 Dec 20121993₹580 Cr (FY 2017)Amalgamated

Explore Director's current and past company associations Uncover their professional journey today!

Board colleagues of Tirunelveli Padmanabhan Devarajan

NameDINCompanyDesignation
Debabrata DasPhasorz Technologies Private Limited , Phasorz Technologies Private LimitedCompany Secretary
Enbasekar Dinadayalane06639696Phasorz Technologies Private Limited , Phasorz Technologies Private LimitedDirector
Samir Rajendra Abhyankar10081649Phasorz Technologies Private Limited , Phasorz Technologies Private LimitedNominee Director
Satish Kannan06639711Phasorz Technologies Private Limited , Phasorz Technologies Private LimitedManaging Director
Sunil Kumar Thakur03266370Phasorz Technologies Private Limited , Phasorz Technologies Private LimitedNominee Director
Vishal Vijay Gupta01913013Phasorz Technologies Private Limited , Phasorz Technologies Private LimitedDirector
Dilip Keshavlal Patel00013150Malladi Drugs And Pharmaceuticals LimitedDirector
Hariharan Sivaramakrishnan10272165Malladi Drugs And Pharmaceuticals LimitedDirector
Kanagasabesan KarthikMalladi Drugs And Pharmaceuticals LimitedCompany Secretary
Karthik KanagasabesanMalladi Drugs And Pharmaceuticals LimitedCompany Secretary
Parvathi Malladi01498852Malladi Drugs And Pharmaceuticals LimitedDirector
Prashant Malladi00133341Malladi Drugs And Pharmaceuticals LimitedWhole-Time Director
Revathi Raghunathan01254043Malladi Drugs And Pharmaceuticals LimitedDirector
Sandip Neogi08121050Malladi Drugs And Pharmaceuticals LimitedCfo
Sandip NeogiMalladi Drugs And Pharmaceuticals LimitedCfo
Shreya Sistla00133354Malladi Drugs And Pharmaceuticals LimitedManaging Director
Subramanian Vishar Vasudevan00130205Malladi Drugs And Pharmaceuticals Limited , Sandor Life Sciences Private LimitedNominee Director
Venganelloor Gopalakrishnan Narayanaswami00198785Malladi Drugs And Pharmaceuticals LimitedWhole-Time Director
Krishna Prasada Rao Vunnam05141577Ankura Medical & Research Centre Private LimitedDirector
Srinidhi Thirunagari05141585Ankura Medical & Research Centre Private LimitedDirector
Rudraraju Sneha09683892Aizant Drug Research Solutions Private LimitedDirector
Sanjeev Kumar Sethi02168682Aizant Drug Research Solutions Private LimitedDirector
Soumya Rudraraju09253303Aizant Drug Research Solutions Private LimitedDirector
Srinivas KotraAizant Drug Research Solutions Private LimitedCompany Secretary
Varma Srinivasa Rajasekara Rudraraju01661426Aizant Drug Research Solutions Private LimitedManaging Director

Directorship timeline

Open interactive timeline →
Malladi Drugs And Pharmaceuticals Limited
Aizant Drug Research Solutions Private Limited
Alniche Lifesciences Private Limited
Phasorz Technologies Private Limited
Premium access

Shareholding and investment profile for Tirunelveli Padmanabhan Devarajan

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Tirunelveli Padmanabhan Devarajan

Tirunelveli Padmanabhan Devarajan currently holds 8 directorships: Phasorz Technologies Private Limited (Nominee Director, since 08 Jan 2021, revenue ₹743 Cr (FY 2025)); Phasorz Technologies Private Limited (Nominee Director, since 08 Jan 2021, revenue ₹743 Cr (FY 2025)); Malladi Drugs And Pharmaceuticals Limited (Nominee Director, since 28 Mar 2022, revenue ₹627 Cr (FY 2025)); Ankura Medical & Research Centre Private Limited (Nominee Director, since 17 Jul 2019, revenue ₹483 Cr (FY 2025)); Aizant Drug Research Solutions Private Limited (Director, since 27 Mar 2017, revenue ₹193 Cr (FY 2023)); and 3 more.

Tirunelveli Padmanabhan Devarajan was first appointed on 14 Mar 2011 as Alternate Director at Fermenta Biotech Limited. The most recent appointment on record is 17 Oct 2022 at Indilyfe Sponsor Llp.

The 7 current companies of Tirunelveli Padmanabhan Devarajan that report revenue have a combined latest revenue of ₹2,915 Cr: Phasorz Technologies Private Limited ₹743 Cr (FY 2025); Phasorz Technologies Private Limited ₹743 Cr (FY 2025); Malladi Drugs And Pharmaceuticals Limited ₹627 Cr (FY 2025); Ankura Medical & Research Centre Private Limited ₹483 Cr (FY 2025); Aizant Drug Research Solutions Private Limited ₹193 Cr (FY 2023); and 2 more.

Tirunelveli Padmanabhan Devarajan held 5 earlier board appointments: Sreyas Holistic Remedies Private Limited (Director, 15 Feb 2014 to 10 Mar 2023); Stericon Pharma Private Limited (Nominee Director, 02 Jan 2017 to 28 Mar 2023); Neuland Pharma Research Private Limited (Director, 07 Dec 2012 to 22 Jun 2017); Fermenta Biotech Limited (Alternate Director, 14 Mar 2011 to 14 Dec 2017); Neuland Health Sciences Private Limited (Alternate Director, 07 Dec 2012 to 22 Jun 2017).

The current boards of Tirunelveli Padmanabhan Devarajan's companies include Debabrata Das (Phasorz Technologies Private Limited), Enbasekar Dinadayalane (Phasorz Technologies Private Limited), Samir Rajendra Abhyankar (Phasorz Technologies Private Limited), Satish Kannan (Phasorz Technologies Private Limited), Sunil Kumar Thakur (Phasorz Technologies Private Limited), Vishal Vijay Gupta (Phasorz Technologies Private Limited), among others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available